Recent Updates
Recently added Catalysts

Lucinactant

Phase 2

COVID-19 | Small molecule | Infectious Disease |Windtree Therapeutics, Inc.|Last Updated: Jun 23, 2023

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical trial landscape

Lucinactant · 2 trials · 3 indications

Phase 2 2
NCT04389671The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)COVID-19
COMPLETED20 Analytics
NCT00578734Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years OldAcute Hypoxemic Respiratory Failure
COMPLETED165 Analytics
PHASE2COMPLETED
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
COVID-19Unlock trial analytics
PHASE2COMPLETED
Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
Acute Hypoxemic Respiratory FailureUnlock trial analytics
Study Endpoints
Primary Endpoints
Oxygen Index (OI)
Baseline through 12 hours post initiation of dosing

Change from baseline in OI. OI is an index value, calculated as (Mean Airway Pressure \[Paw\]) x (Fraction of Inspired Oxygen \[FiO2\]) x (100) / (Partial Pressure of Oxygen \[PaO2\]) measured using mean and standard deviation. It is a calculation that measures the fraction of inspired oxygen and its usage within the body, and a lower value is better. Values can range from 0 to 1000; values under 25 are correspond with a good outcome.

Duration of Mechanical Ventilation Through 14 Days
Up to 14 Days

Duration of mechanical ventilation (MV) from baseline to successful extubation (not receiving MV for at least 24 hours) through a maximum of 14 days.

Secondary Endpoints
Fraction of Inspired Oxygen (FiO2)
Baseline through 24 hours post initiation of dosing
Partial Pressure of Oxygen (PaO2)
Baseline through 24 hours post initiation of dosing
Oxygenation From Pulse Oximetry (SpO2)
Baseline through 24 hours post initiation of dosing
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Lyophilized LucinactantEXPERIMENTALLyophilized Lucinactant reconstituted with sterile water for injection
LucinactantEXPERIMENTALSURFAXIN® (lucinactant) for intratracheal instillation
Sham AirSHAM_COMPARATORSham air (placebo) instillation
Interventions
NameTypeDescription
LucinactantDRUGLucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
Sham ComparatorOTHERSlow intra-tracheal instillation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * Signed and dated informed consent form (ICF) by the subject or legally authorized representative; * Age 18-75 (inclusive); * Assay positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, preferably by polymerase chain reaction (PCR); * Endotracheal int...

Countries:United StatesArgentinaChile
Unlock Eligibility Criteria